Investors Sell Shares of Bristol-Myers Squibb Company (BMY) on Strength (BMY)

Traders sold shares of Bristol-Myers Squibb Company (NYSE:BMY) on strength during trading hours on Tuesday. $32.62 million flowed into the stock on the tick-up and $62.15 million flowed out of the stock on the tick-down, for a money net flow of $29.53 million out of the stock. Of all companies tracked, Bristol-Myers Squibb had the 0th highest net out-flow for the day. Bristol-Myers Squibb traded up $0.26 for the day and closed at $61.25

Several analysts have issued reports on BMY shares. UBS AG restated a “buy” rating and set a $72.00 price objective (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Vetr upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 price objective on the stock in a research note on Monday, October 9th. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. BMO Capital Markets restated a “sell” rating and set a $49.00 price objective on shares of Bristol-Myers Squibb in a research note on Monday, September 4th. Finally, Citigroup Inc. increased their price target on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $64.93.

The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The stock has a market capitalization of $99,822.34, a P/E ratio of 20.60, a PEG ratio of 2.40 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.77 earnings per share. analysts anticipate that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 2.55%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is currently 61.42%.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the transaction, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.23% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.3% during the 2nd quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock worth $6,611,829,000 after acquiring an additional 333,685 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Bristol-Myers Squibb by 2.4% during the 2nd quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock worth $5,541,612,000 after acquiring an additional 2,367,864 shares in the last quarter. State Street Corp boosted its stake in shares of Bristol-Myers Squibb by 1.8% during the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after acquiring an additional 1,223,457 shares in the last quarter. Dodge & Cox boosted its stake in shares of Bristol-Myers Squibb by 1.6% during the 2nd quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock worth $1,648,168,000 after acquiring an additional 459,271 shares in the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of Bristol-Myers Squibb by 16.2% during the 3rd quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock worth $1,711,689,000 after acquiring an additional 3,735,453 shares in the last quarter. 69.51% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Investors Sell Shares of Bristol-Myers Squibb Company (BMY) on Strength (BMY)” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/11/15/investors-sell-shares-of-bristol-myers-squibb-company-bmy-on-strength-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply